

<b>KOPRAN LIMITED</b>				
<b>UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30th JUNE,2013</b>				
<b>Part I</b>				(Rupees in Lakhs)
<b>Particulars</b>	Quarter ended			Year ended
	30/06/2013	31/03/2013	30/06/2012	31/03/2013
	Unaudited	Audited	Unaudited	Audited
Net Sales / Income from Operations	5810	7455	4,968	24,330
Other Operating Income	160	219	132	692
<b>Total Income from operations</b>	<b>5970</b>	<b>7674</b>	<b>5100</b>	<b>25022</b>
<b>Expenditure</b>				
Changes in Inventories of Finished Goods, Work-in- Progress and stocks- in-trade	(256)	300	(444)	(408)
Cost of Materials Consumed	3869	4568	3,482	15,823
Purchase of Stock- in - trade	60	-	-	-
Employee Benefits Expenses	524	643	417	2,048
Depreciation	303	305	296	1,208
Other Expenses	990	1140	886	4,129
<b>Total Expenses</b>	<b>5490</b>	<b>6956</b>	<b>4,637</b>	<b>22,800</b>
<b>Profit (Loss) from operations before other income, Interest and exceptional items</b>	480	718	463	2,222
Other Income	106	39	60	172
<b>Profit (Loss) before Interest and exceptional items</b>	586	757	523	2,394
Finance Cost	307	351	272	1,188
<b>Profit (Loss) before exceptional items</b>	<b>279</b>	<b>406</b>	<b>251</b>	<b>1,206</b>
Exceptional items	-	-	-	-
<b>Profit ( Loss ) before tax</b>	<b>279</b>	<b>406</b>	<b>251</b>	<b>1,206</b>
Less :Tax expenses	-	-	-	-
<b>Net Profit for the period</b>	<b>279</b>	<b>406</b>	<b>251</b>	<b>1,206</b>
Paid up equity share Capital (Face value Rs 10/-)	3,905	3,905	3,905	3,905
Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	8,048
<b>Earning Per Share ( EPS ) before and after Exceptional Item</b>				
a) Basic	0.71	1.04	0.64	3.09
b) Diluted	0.71	1.04	0.64	3.09
<b>Part II</b>				
<b>(A) PARTICULARS OF SHAREHOLDING</b>				
Public shareholding				
Number of shares	23956538	25510073	25809523	25510073
Percentage of shareholding	61.35%	65.33%	66.09%	65.33%
<b>Promoters and Promoter Group Shareholding</b>				
<b>a) Pledged / Encumbered</b>				
Number of shares	1852500	1852500	552500	1852500
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	12.27%	13.68%	4.17%	13.68%
Percentage of shares (as a % of the total share capital of the company)	4.74%	4.74%	1.42%	4.74%
<b>b) Non - encumbered</b>				
Number of shares	13240428	11686903	12687453	11686903
Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	87.73%	86.32%	95.83%	86.32%
Percentage of shares (as a % of the total share capital of the company)	33.91%	29.93%	32.49%	29.93%
<b>(B) INVESTOR COMPLAINTS</b>	3 Months ended 30/06/2013			
Pending at the beginning of the quarter	-			
Received during the quarter	1			
Disposed off during the quarter	1			
Remaining unresolved at the end of the quarter	-			

<b>Reporting of Segment wise Revenue,Result and Capital Employed</b>				
<b>Particulars</b>	Quarter ended			Year ended
	30/06/2013	31/03/2013	30/06/2012	31/03/2013
	Unaudited	Audited	Unaudited	Audited
<b>1. Segment Revenue</b>				
(a) Pharamaceutical	6,110	7,829	5,265	25,734
(b) Consumer Care Division	42	-	-	-
<b>Total</b>	<b>6,152</b>	<b>7,829</b>	<b>5,265</b>	<b>25,734</b>
Less : Inter-Segment Revenue	-	-	-	-
Less : Excise Duty	182	155	165	712
<b>Net Sales/ Income from Operation</b>	<b>5,970</b>	<b>7,674</b>	<b>5,100</b>	<b>25,022</b>
<b>2. Segment Results</b>				
(a) Pharamaceutical	615	757	523	2,394
(b) Consumer Care Division	(29)	-	-	-
<b>Total</b>	<b>586</b>	<b>757</b>	<b>523</b>	<b>2,394</b>
Less: Finance Cost	307	351	272	1,188
<b>Total Profit Before Tax</b>	<b>279</b>	<b>406</b>	<b>251</b>	<b>1,206</b>
<b>3. Capital Employed</b>				
(a) Pharamaceutical	18,167	17,631	15,744	17,631
(b) Consumer Care Division	35	-	-	-
(c) Others (Unallocated)	5,481	5,419	5,379	5,419
<b>Total</b>	<b>23,683</b>	<b>23,050</b>	<b>21,123</b>	<b>23,050</b>
<b>Notes:-</b>				
(1) The above results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at it's meeting held on 10th August,2013. Limited review has been carried out by statutory auditor of the company.				
(2) During the quarter the company has launched Tooth Paste under "Sparkle" brand in consumer care division.				
<b>(3) Auditors observation:</b>				
a) Investments and Advances made to Subsidiary Company, Koprán Research Laboratories Ltd (KRLl) as at 30-06-2013 amounting to Rs. 5294.53 Lacs,(as at 30-06-2012 Rs.5192.38 Lacs) are in the opinion of the Auditors doubtful of realisation. In the opinion of the Management, no provision is required to be made because the investment in the Subsidiary Company, KRLl, is long term, for strategic reasons.				
(4) Other Income includes net exchange Gain of Rs.103.85 lacs (quarter ended 30th June 2012 Gain of Rs.13.98 lacs)				
(5) Figures for the previous accounting period have been regrouped wherever necessary.				
<b>KOPRAN LIMITED</b>				
<b>Surendra Somani</b>				
<b>Executive Vice Chairman</b>				
Place : Mumbai				
Date: 10-08-2013				